ArticleWorld journal of surgical oncology2026
Pathological subtype dictates survival and failure pattern in laryngeal neuroendocrine neoplasms: a 15-year single-institution experience.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLaryngeal neuroendocrine neoplasms (LNENs) comprise < 1% of laryngeal malignancies, and evidence-based treatment guidelines remain lacking. We sought to delineate clinicopathological features, therapeutic strategies, and survival determinants in a single-institution cohort of consecutive patients with primary LNEN.
methodsWe retrospectively identified 31 consecutive patients with primary LNEN treated between 2010 and 2024. Histology was centrally reviewed by two head-and-neck pathologists and categorized as well-differentiated neuroendocrine tumor (NET, G1-G3) or poorly differentiated neuroendocrine carcinoma (NEC, small-cell/large-cell). All cases underwent immunohistochemistry (Syn, CgA, Ki-67) and multidisciplinary therapy. Survival analyses were performed with Kaplan-Meier and Cox proportional-hazards models.
resultsMedian age was 60 years, 90.3% were male, and 80.6% had a smoking history. NEC accounted for 71% (22/31) and NET for 29% (9/31). NEC exhibited higher Ki-67 index (85% vs. 10%, P < 0.001), more advanced stage (63.6% vs. 33.3%, P = 0.013), and a predilection for distant metastasis (85.7% vs. 25.0%, P = 0.002). Median overall survival (OS) was 27.0 months for NEC vs. not reached for NET (P < 0.001); 5-year OS was 0% vs. 44.4%. Median disease-free survival (DFS) was 19.0 vs. not reached (P < 0.001). Multivariate analysis identified NEC subtype (HR = 4.23, 95% CI 1.39-12.90), T3-4 stage (HR = 2.61, 95% CI 1.02-6.66), and lymph nodal positivity (HR = 3.12, 95% CI 1.20-8.10) as independent predictors of poor OS; NEC subtype (HR = 3.67, 95% CI 1.15-11.70) and N+ (HR = 3.51, 95% CI 1.22-10.10) predicted inferior DFS. Distant metastasis was the first mode of failure in 68.9% of curative-intent cases.
conclusionsPathologic subtype (NEC vs. NET) emerges as the dominant independent predictor of survival in this cohort. NEC demonstrates a systemic biological phenotype characterized by early distant metastasis. These findings support the hypothesis that intensified perioperative systemic therapy, rather than locoregional escalation, warrants prospective investigation. Multi-center, molecularly stratified trials are needed to establish a precision-medicine paradigm for this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.